A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
NCT04098575 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9571
Last updated 2021-03-29
Summary
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
Empagliflozin
drug
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-09-16
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
- FDA Drug
- Yes
Countries
- Germany
Study Locations
More Related Trials
-
The Effects of Empagliflozin on Arterial Wall Characteristics
NCT03639545 ·Status: UNKNOWN ·Phase: PHASE4
-
Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT03249506 ·Status: COMPLETED
-
Dapagliflozin Effect on Erythropoiesis and Physical Fitness
NCT03423355 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT06642272 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495 ·Status: COMPLETED ·Phase: PHASE2
-
Empagliflozin and Cardiac Remodelling in People Without Diabetes
NCT04461041 ·Status: COMPLETED ·Phase: PHASE4
-
Empagliflozin in Treatment of Peripheral Diabetic Neuropathy
NCT05977465 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
NCT06054035 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
NCT02998970 ·Status: UNKNOWN ·Phase: PHASE4
-
Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin
NCT02899949 ·Status: COMPLETED
-
Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
NCT02932436 ·Status: COMPLETED ·Phase: PHASE4
-
Novel Therapeutics and Endothelial Dysfunction in T1DM Patients
NCT05857085 ·Status: COMPLETED ·Phase: PHASE4
-
Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey
NCT03407196 ·Status: COMPLETED
-
Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.
NCT03338855 ·Status: COMPLETED ·Phase: PHASE4
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
Renoprotective Effects of Dapagliflozin in Type 2 Diabetes
NCT02682563 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
NCT04961931 ·Status: UNKNOWN ·Phase: NA
-
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
NCT04203927 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD)
NCT06391450 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Empa PASS on Urinary Tract Malignancies
NCT03464045 ·Status: COMPLETED
-
Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes
NCT02372955 ·Status: UNKNOWN ·Phase: PHASE4
-
REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations
NCT04243850 ·Status: WITHDRAWN ·Phase: PHASE4
-
Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes
NCT05139914 ·Status: TERMINATED ·Phase: PHASE4